Bi Asset Management Fondsmaeglerselskab A Halozyme Therapeutics, Inc. Transaction History
Bi Asset Management Fondsmaeglerselskab A
- $6.11 Billion
- Q2 2024
A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 23,632 shares of HALO stock, worth $1.38 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
23,632
Previous 14,577
62.12%
Holding current value
$1.38 Million
Previous $593,000
108.6%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding HALO
# of Institutions
514Shares Held
124MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$753 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$340 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$236 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$217 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.14B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...